NCT03374657View on ClinicalTrials.gov

A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

May 11, 2026

Study Completion Date

May 11, 2026

Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL

CPK850

In one of 4 dose levels administered via subretinal injection under anesthesia

Trial Locations (1)

SE-112 82

Novartis Investigative Site, Stockholm

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY